Hufnagel, Fathi et al. use an antibody microarray-based approach to identify plasma protein biomarkers present during the early phases of SARS CoV-2 infection that distinguish people who will go on to develop severe COVID-19. A multimarker panel of proteins enables people at high risk of developing a severe or critical disease course to be identified.
- Katrin Hufnagel
- Anahita Fathi
- Christoph Schröder
